Scarica l'app Stockscreener
38.95
1.43%
0.55
Pre-mercato:
38.56
-0.39
-1.00%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Gsk Plc Adr Borsa (GSK) Ultime notizie
Validea Detailed Fundamental AnalysisGSK - Nasdaq
The 10 Best Companies to Invest in Now - Morningstar
Regeneron, Sanofi Stock Falls After Uneven Smoker's Lung Drug Data - Benzinga
Penicillin Market Research Report 2025 - GlobeNewswire Inc.
Is GSK PLC Sponsored ADR (GSK) Outperforming Other Medical Stocks This Year? - Yahoo Finance
The Best Healthcare Stocks to Buy - Morningstar
FDA Approves GSK's Nucala for Expanded Use in COPD - Yahoo Finance
Why Value Investing Has Worked Better Outside the US - Morningstar
GSK Inks $2B Deal With Boston Pharmaceuticals to Buy Liver Disease Drug - Yahoo Finance
Ratios in Focus: Analyzing GSK Plc ADR (GSK)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
There Is A Lot Of Upside Potential For GSK Plc ADR(NYSE: GSK) - Stocksregister
Here's Why GSK (GSK) is a Strong Growth Stock - Nasdaq
GSK Q1 Earnings Beat, Sales Lag, Stock Gains on Tariff Reassurance - TradingView
GSK Plc ADR [GSK] gain 15.23% so far this year. What now? - dbtnews.com
GSK’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - investchronicle.com
GSK to Report First-Quarter Earnings: Is a Beat in Store? - Nasdaq
An analyst sees good growth prospects for GSK Plc ADR (GSK) - Sete News
GSK Plc ADR [GSK] Investment Guide: What You Need to Know - knoxdaily.com
Analysts Estimate GSK (GSK) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
GSK’s Market Whiplash: 8.94% YTD Rise, -6.10% Plunge in 30 Days - investchronicle.com
GSK Securities Class Action: GSK PLC Investors Should Contact Robbins LLP for Information About the Lead Plaintiff Deadline in the GSK Class Action Lawsuit - Finansavisen
GSK's Pentavalent Meningococcal Jab Recommended for Use by ACIP - TradingView
Best International Companies to Own: 2025 Edition - Morningstar
Deadline Alert: GSK plc. (GSK) Investors Who Lost Money - GlobeNewswire
Deadline Alert: GSK plc. (GSK) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit - TradingView
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in GSK plc of Class Action Lawsuit and Upcoming DeadlinesGSK - Finansavisen
Is GSK plc (GSK) the Best ADR Stock to Buy According to Hedge Funds? - Insider Monkey
GSK's Vaccine and HIV Portfolios Support Ongoing Innovation in Oncology and Immunology - Morningstar
GSK FINAL DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, - GlobeNewswire
GSK Secures FDA Nod for Oral Antibiotic to Treat Urinary Tract Infection - Yahoo Finance
GSK Investors Have Opportunity to Lead GSK plc Securities Fraud Lawsuit - PR Newswire
Best international companies to own: 2023 Edition - Morningstar
How Do Things Look For GSK Plc ADR (NYSE: GSK) In The Short-Term? - Stocks Register
GSK Lead Plaintiff Deadline Approaching – Contact Robbins - GlobeNewswire
GSK Lead Plaintiff Deadline Approaching – Contact Robbins LLP for Information About How to Lead the GSK PLC Class Action - TradingView
Why GSK (GSK) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Bioengineered Protein Drugs Market Size to Cross USD 672.7 Billion by 2034, Growing at a CAGR of 6.2% - GlobeNewswire Inc.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick - Yahoo Finance
1.53%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):